This is a collection of blog posts written by Lucinda K. Porter, RN, a hepatitis C writer who attended this year’s Conference on Retroviruses and Opportunistic Infections (CROI). The blog posts below highlight hepatitis C studies presented at the conference that stood out to her.
Please scroll down and click on the blog tittles that interest you.
Sampling of CROI 2017 Meeting Highlights Written by Lucinda K. Porter, RN
- People With HIV, Hep C and Decompensated Cirrhosis Do Well on Hep C Treatment: But not as well as those with compensated cirrhosis or no cirrhosis
- People With HIV, Hepatitis C and Cirrhosis Can Do Very Well on Hep C Treatment
- Hepatitis C in Seattle: Reports From CROI: Highlights from the hep C-related studies presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle
- Hepatitis C Is Spreading Sexually Among HIV-Negative Gay and Bi Men in Amsterdam: Hep C infection routes among this population apparently overlap with those of their HIV-positive peers.
- Among People With HIV, Treating Hep C Improves Indicators of Overall Health: However, in a recent small study, hepatitis C treatment was not associated with an improvement in cognitive impairment in this population.
- Injection Drug Users Can Do Well on Hepatitis C Treatment: Eighty-five precent of IDUs receiving hep C therapy at a New York City syringe exchange program were cured
The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.
More information about the CROI and the studies that were presented there can also be found in our blog post CROI 2017 Hep C Highlights Part I.
“Creating a world free from hepatitis C one step at a time” -Lucinda Porter